Drug · Small Molecule

Crizotinib

CI-DRUG-00000165Explore in graph →NCIt C74061 CHEMBL601719 CIViC Approved

Regulatory

Approvals (17)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

health-canada-dpdRegulatory17 approval records from 3 sources (hover a row badge for its dataset) · authority, jurisdiction and indication text as published.

Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
CA Health Canada	—	Marketed in Canada as XALKORI (DIN 02384256) under ATC L01ED01 CRIZOTINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	May 10, 2012	health-canada-dpd
CA

Health Canada records are DIN-level: one row per marketed product (brand, strength, form). The Drug Product Database does not publish indications, so no cancer is stated for these rows, and a cancelled or dormant DIN is the status of that one product — not a withdrawal of the molecule.

Data updated 2 days agoSource updated unknown

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Approvals	Jurisdictions	First approval	First trial
All cancers	Approved	Phase 4	27	11	21	90	17	CA, EU, US	Aug 26, 2011	Mar 7, 2003
Non-Hodgkin Lymphoma	Approved	Phase 4	7	1	0	15	4	US	Aug 26, 2011	Apr 19, 2006
Malignant Lung Neoplasm	Phase4	Phase 4	15	4	16	44	0	—	—	2009-09
Multiple Myeloma	Phase2	Phase 2	6	1	0	6	0	—

Curated evidence

Clinical evidence (267)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 251–267 of 267 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
ALK R1275Q4
Crizotinib	Neuroblastoma

Clinical trials

Trials with this intervention (100)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–50 of 100 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02194738	Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)	active not recruiting	N/A	7,458	National Cancer Institute (NCI)NIH	3	Sep 23, 2026	clinicaltrials
NCT06140836	A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)

Molecule

Record

Kind: Small Molecule
Mechanism: Hepatocyte growth factor receptor inhibitor; ALK tyrosine kinase receptor inhibitor; EML4-ALK inhibitor; NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) inhibitor; Proto-oncogene tyrosine-protein kinase ROS inhibitor; Macrophage-stimulating protein receptor inhibitor
Targets: 6 genes
UNII: 53AH36668S
Aliases: 2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-, Alkixen, Crizocent, Crizotinib, MET Tyrosine Kinase Inhibitor PF-02341066, NSC-756645, PF 02341066, PF-02341066, PF02341066, PF-2341066, (R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine, Xalkori, XALKORI

Data updated 22 hours agoSource updated unknown

Identifiers

Codes (6)

Upstream identifiers kept as first-class codes; each links to its registry where a stable public URL exists.

System	Code	Label
ATC (WHO)	L01ED01	CRIZOTINIB
DIN (Health Canada)	02384256

ALK Fusion4
Crizotinib	Thyroid Gland Anaplastic CarcinomaALIAS	Predictive	C	Supports Sensitivity Response	3	accepted	EID5954 A patient with anaplastic thyroid carcinoma harboring ALK rearrangement received crizotinib after chemotherapy for pulmonary recurrence. Crizotinib showed confirmed response of more than 90% by tumor … (full text at CIViC) PMID 24687827 · Godbert et al., 2015 · Open in CIViC	civic
〃	Vaginal SarcomaALIAS	Predictive	C	Supports Sensitivity Response	2	accepted	EID6042 Patient was 34-year-old woman with vaginal sarcoma, which was excised with positive surgical margins. Fluorescence in situ hybridization testing of her tumor revealed anaplastic lymphoma kinase gene … (full text at CIViC) PMID 26942346 · Forde et al., 2016 · Open in CIViC	civic
〃	Epithelioid Inflammatory Myofibroblastic SarcomaUNRESOLVED	Predictive	C	Supports Sensitivity Response	2	accepted	EID6043 This is a case report of a 22-year-old Japanese man with a pelvic mesenchymal neoplasm. Tumor analysis include IHC and RT-PCR led to diagnosis of epithelioid inflammatory myofibroblastic sarcoma with… (full text at CIViC) PMID 25028698 · Kimbara et al., 2014 · Open in CIViC	civic
Alectinib + Crizotinib + EntrectinibSubstitutes	Gastrointestinal CarcinomaUNRESOLVED	Predictive	C	Supports Sensitivity Response	3	submitted	EID10324 Retrospective analysis of patients with ALK-fusion positive gastrointestinal cancers. 13 patients were identified (5 pancreas, 3 right-sided colon, 1 gastric, 1 duodenal, 1 rectal, 1 left-sided colon,… (full text at CIViC) PMID 35476549 · Ambrosini et al., 2022 · Open in CIViC	civic

MET Overexpression2
Crizotinib	Uveal Melanoma	Predictive	D	Supports Sensitivity Response	1	accepted	EID1583 c-MET and ligand HGF were expressed by 6 uveal melanoma cell lines in-vitro. GNA-mutant cell lines (n=3) showed stronger expression of ligand and receptor as well as more receptor phosphorylation. SiR… (full text at CIViC) PMID 24140933 · Surriga et al., 2013 · Open in CIViC	civic
〃	Uveal Melanoma	Predictive	E	Supports Sensitivity Response	2	rejected	EID1582 Preclinical study in uveal melanoma cell lines. c-MET was identified as a transcriptional target of miR-144. miR-144 was downregulated in 4 uveal melanoma cell lines and 5 human uveal melanoma tumor t… (full text at CIViC) PMID 25961751 · Sun et al., 2015 · Open in CIViC	civic